Tg Therapeutics (TGTX) Receivables - Net (2021 - 2025)
Tg Therapeutics has reported Receivables - Net over the past 5 years, most recently at $305.6 million for Q4 2025.
- Quarterly results put Receivables - Net at $305.6 million for Q4 2025, up 136.58% from a year ago — trailing twelve months through Dec 2025 was $305.6 million (up 136.58% YoY), and the annual figure for FY2025 was $305.6 million, up 136.58%.
- Receivables - Net for Q4 2025 was $305.6 million at Tg Therapeutics, up from $265.4 million in the prior quarter.
- Over the last five years, Receivables - Net for TGTX hit a ceiling of $305.6 million in Q4 2025 and a floor of $88000.0 in Q2 2022.
- Median Receivables - Net over the past 5 years was $45.2 million (2023), compared with a mean of $83.8 million.
- Biggest five-year swings in Receivables - Net: crashed 90.55% in 2022 and later soared 19768.18% in 2023.
- Tg Therapeutics' Receivables - Net stood at $1.4 million in 2021, then tumbled by 93.66% to $88000.0 in 2022, then skyrocketed by 57960.23% to $51.1 million in 2023, then surged by 152.84% to $129.2 million in 2024, then surged by 136.58% to $305.6 million in 2025.
- The last three reported values for Receivables - Net were $305.6 million (Q4 2025), $265.4 million (Q3 2025), and $231.5 million (Q2 2025) per Business Quant data.